SINTX Technologies Reports 46% Revenue Decline and $2.3 Million Net Loss in Q1 2025

SINTX Technologies, Inc. reported its financial results for the first quarter of 2025, revealing a total revenue of $369,687, a decrease of 46% compared to $687,000 in the same period of 2024. The decline was primarily driven by a significant drop in grant and contract revenue, which fell by 79% to $78,000 from $378,000. Product revenue remained relatively stable, totaling $291,000, down from $309,000. The company incurred a net loss of $2.3 million, compared to a loss of $886,000 in the prior year, reflecting a 159% increase in losses.

In terms of operational efficiency, SINTX Technologies managed to reduce its total operating expenses by 32% to $2.5 million, down from $3.7 million in the previous year. This reduction was largely attributed to a 45% decrease in research and development expenses, which fell to $1.1 million from $2.0 million, as well as a significant cut in grant and contract expenses. The company’s loss from operations improved by 25%, decreasing from $3.2 million to $2.4 million.

Strategically, SINTX Technologies has made notable changes, including the sale of its subsidiary, Technology Assessment and Transfer, Inc. (TA&T), to Tethon Corporation on February 19, 2025. This transaction is expected to positively impact the company's financials by reducing liabilities. Additionally, the company raised $5 million through a private placement of common stock and warrants, which closed on February 25, 2025. This capital is intended for general corporate purposes and working capital, as SINTX continues to seek opportunities for growth in the biomedical sector.

As of March 31, 2025, SINTX reported total assets of $11.4 million, an increase from $9.4 million at the end of 2024, driven by a rise in cash and cash equivalents to $6.5 million from $3.6 million. The company’s accumulated deficit stood at $284 million, up from $282 million at the end of the previous fiscal year. The workforce has also been streamlined, with a reduction in headcount aimed at improving operational efficiency.

Looking ahead, SINTX Technologies acknowledges the need for substantial future capital to support ongoing operations and product development. The company is focused on enhancing its sales strategy and expanding its market presence, particularly in the medical device sector, where it aims to leverage its expertise in advanced ceramics. However, the company’s ability to achieve profitability and secure additional financing remains uncertain, contingent on its operational performance and market conditions.